Peptide Injection Calculator

A peptide calculator works out the exact liquid volume you need to draw up to inject a given dose. Because peptides ship as a freeze-dried powder (the technical term is lyophilisate), you first mix them with bacteriostatic water (BAC - a sterile water with a preservative that stops bacteria from growing, keeping it usable for several withdrawals). The calculator removes the guesswork from converting milligrams of powder into millilitres on the syringe.

Peptides are highly potent - meaning they work extremely strongly even in the tiniest amounts. Because even the smallest measuring error with the liquid leads to a large over- or underdose, a wrong dose can reduce effectiveness or cause side effects. The calculation matters because tiny volume differences translate into large dose differences. The calculator removes the risk of human arithmetic errors and ensures you get the exact right dose every time.

BAC stands for 'bacteriostatic water' - literally 'bacteria-inhibiting water'. It contains about 0.9% benzyl alcohol (the preservative that does the bacteria-inhibiting job), which stops bacteria from multiplying in an opened vial (small glass bottle). You need it to dissolve freeze-dried peptide powder in the vial so you can inject it over several days. It matters because it lets you store a vial of dissolved peptide in the fridge and draw from it several times without bacteria growing in it. Never use tap water or boiled water for injections.

The peptide comes as a powder in the vial. You add a measured amount of water to dissolve it, then draw up only part of that liquid, exactly the part that contains your target dose. Here's how to calculate that part:

Volume to draw up (ml) = (target dose ÷ vial strength) × BAC water (bacteriostatic water, sterile water used to dissolve the powder) added. Example: 250 mcg target (1 mg = 1,000 mcg), 5 mg (5,000 mcg) vial, 2 ml water → (250 ÷ 5,000) × 2 = 0.1 ml. On a U100 insulin syringe (where 1 ml = 100 units), 0.1 ml = 10 units (IU, International Units). This formula always converts your target dose into a volume you can read on the syringe.

For dose calculation, the syringe size is irrelevant as long as the U-100 scale is used: On every U-100 insulin syringe, 100 units (IU) equal exactly 1 milliliter, so one unit always equals 0.01 milliliters. It follows that 50 IU = 0.5 ml, 20 IU = 0.2 ml, and 10 IU = 0.1 ml. The stated capacity only determines the maximum total volume.

The scale must not be confused with the fill volume. U-100 syringes come in three common sizes: 0.3 milliliters hold 30 units, 0.5 milliliters hold 50 units, and 1 milliliter holds 100 units. The most common size for peptide injections is the 0.5-milliliter syringe; a full milliliter does not fit in it.

On the scale, a single tick mark represents different amounts depending on the model. Syringes with 0.3 milliliters usually have markings for half or whole units, syringes with 0.5 milliliters for whole units, and syringes with 1 milliliter for whole or double units. With double divisions, one small tick equals 0.02 milliliters. Before any calculation, read carefully what value the tick marks on your syringe indicate.

A finer scale does not automatically lead to higher dosing accuracy in practice. In a comparative study, half-unit markings improved neither accuracy nor repeatability, and when measuring a single unit (0.01 milliliters), the tested syringes were clinically dangerously inaccurate. Smaller syringes are easier to read because the ticks are farther apart; handling matters, not the fineness of the scale.

With the rarer U-40 scale, 40 units equal exactly 1 milliliter, so one unit equals 0.025 milliliters. This scale is mainly common with certain animal insulins; if U-100 and U-40 are confused, the dosage deviates by more than double. Therefore, always pay attention to the U-100 or U-40 marking on the syringe. The correct volume is provided by the injection calculator.

Choose a practical amount: not too little (dissolves poorly, stings) and not too much (the injection volume becomes too large). For standard vials (5-10 mg, the small peptide vials with a rubber stopper), 2-3 ml is a proven default. Use BAC water (bacteriostatic water - sterile water with a preservative, the standard diluent for peptides). In short: more water lowers the concentration, so you need to pull more liquid into the syringe for the same dose.

Yes. More water lowers the concentration, so you draw up a larger volume for the same dose; less water does the opposite. You don't have to calculate yourself: once you change the water volume in the calculator, it automatically adjusts the volume for you.

1. Recalculate the concentration
   What you do: work out the actual concentration.
   Formula: concentration (mg/ml) = peptide in the vial (mg) ÷ water actually added (ml).
   Help: run it through the dose guide.
2. Find the volume per dose
   What you do: figure out how many ml to draw up.
   Formula: volume per dose (ml) = desired dose (mg) ÷ actual concentration.
   Convert for the syringe: on a U-100 syringe (the standard insulin syringe - 100 units equal exactly 1 ml) multiply by 100 to get insulin units. Or use the shortcut: units (IU - International Units, the markings on the syringe) × 0.01 ml = ml per dose.
3. Work out remaining doses
   Formula: remaining doses = leftover volume in vial ÷ volume per dose.
4. Use up the vial, then start fresh
   What you do: finish the remaining vial, then mix a new one correctly.

Work it out: if your vial already came up short, the reverse dose calculator reconstructs how many mg you really had per injection.

Short version: "Research peptides" are lab chemicals, not approved medicines. Anyone who sells them as "for research only" but simultaneously advertises healing, weight loss, or anti-aging is operating in a legal gray zone.

Research peptides (usually labeled 'Research Use Only', or RUO) are chemicals intended for in-vitro laboratory work (i.e., in test tubes, outside a living body) - not approved for human use and with no marketing authorization from any health authority. Approved peptide medicines such as semaglutide (Ozempic/Wegovy) or tirzepatide (Mounjaro/Zepbound), by contrast, have completed a full, multi-year regulatory review (in the US via official approval filings such as an NDA or BLA - NDA stands for New Drug Application for chemical drugs, BLA for Biologics License Application for biologics; in the EU via the EMA), are produced under cGMP (current Good Manufacturing Practice - strict, regulator-audited manufacturing standards), carry a reviewed label with the approved medical use (indication), dose, and warnings, and are dispensed by prescription through licensed pharmacies.

A useful everyday analogy: cGMP and regulatory approval work a bit like a vehicle inspection sticker - without it, the car may still drive, but it is not legally allowed on the road.

The key principle: under the FD&C Act (Section 201(g)), a product is legally a drug based on its claimed 'intended use' - which means an 'RUO' sticker does not protect a vendor who simultaneously markets weight loss, diabetes cure, or anti-aging benefits. The FDA has been closing this gap with warning letters to peptide shops.

• Approved drug: reviewed indication, dose, and manufacturing - verifiable in the Drugs@FDA database and the current DailyMed label.
• RUO research peptide: no reviewed indication, no reviewed dose, no reviewed manufacturing - 'RUO' is a vendor sticker, not an official status.
• Compounded peptide (a peptide prepared individually by a pharmacy): a preparation made individually by a specially licensed US pharmacy (registered under FDA rule 503A) against an individual prescription; only lawful with bulk substances (the approved raw active ingredients) on the FDA list, otherwise still legally an "unapproved new drug" - meaning it is treated by regulators like an illegally marketed medicine.

Which peptides are actually approved and what risks the gray market carries, I summarize in the FAQ on peptide quality and gray-market risks.

What this means for you: Peptides sold as "research" but marketed with anti-aging, weight loss, or diabetes-cure claims are legally unapproved medicines - stay away. Approved peptide medicines are only available through a doctor's prescription and a licensed pharmacy.

The half-life (t½) of a peptide is the time required for its concentration in the blood to decrease by 50 percent. This key pharmacokinetic parameter directly determines the injection interval-that is, whether a peptide is administered multiple times daily or just once weekly. A short half-life of a few minutes requires more frequent doses, while a long half-life of several days enables stable drug levels with less frequent dosing.

A prominent example is semaglutide (Ozempic, Wegovy), which has an elimination half-life of about seven days, making a weekly injection sufficient. According to the package insert, the active substance remains detectable in the body for roughly five to seven weeks after the last dose. In contrast, unmodified peptides such as BPC-157 often have a half-life of only minutes to hours, which may necessitate multiple daily applications.

Two additional technical terms are also relevant for understanding peptide pharmacokinetics:

• Steady state: This stable blood concentration is typically reached after four to five half-lives-for long-acting peptides like semaglutide, that means after about one month of consistent use.
• Accumulation: Drug accumulation occurs when the dosing interval is shorter than the half-life, until the steady-state equilibrium is established.

In practice, it is advisable to check the half-life in the respective peptide profile or the certificate of analysis (CoA) beforehand. This value is crucial for planning the injection frequency and explains the differences between daily and weekly use. Further explanations of pharmacological basics can be found in our glossary. The classification of half-life in the profiles provides objective guidance beyond marketing claims.

This is general pharmacology, not a dosing or application recommendation.

Labels like "For Research Use Only. Not for human use" or "Nur für Forschungszwecke" are a regulatory notice, not a marketing slogan. In the US, this is primarily governed by 21 CFR 809.10(c)(2)(i): A product in the laboratory research phase may carry this label if it is not marketed as an effective diagnostic or therapeutic. It means: The peptide is a laboratory chemical, not an approved drug - it has not been tested for purity, sterility, pyrogenicity, or efficacy in humans, as would be required for an FDA-approved medication.

What matters is the distinction between the label and the actual intended use. The FDA makes clear: Simply printing "Research Use Only" does not exempt a product from drug regulation. What counts is how it is marketed and used. If a vendor simultaneously promotes the peptide with health claims, dosages, or "for your health," the RUO exemption collapses - the FDA can then classify the product as an unapproved drug and take action against the seller.

For you as a buyer, this means in practice:

• The label does not relieve you of personal responsibility: You bear the risks associated with an unapproved substance (purity, sterility, dosage).
• If a shop makes therapeutic promises but also prints "for research use only," that is a classic warning sign - not legal protection for you.
• Approved peptide drugs (such as semaglutide as Ozempic/Wegovy or tirzepatide as Mounjaro) are recognizable by their approval and prescription requirement - they do not carry this clause.

I explain the fundamental distinction between a laboratory chemical and an approved peptide drug in detail in the FAQ Research Peptide vs. Approved Drug. You can find how to check a specific source for legitimacy in the Vendor Radar.

For most peptides you inject under the skin, a U-100 insulin syringe with a volume of 0.3 or 0.5 ml, a needle length of 8 mm (5/16 inch), and a gauge of 29 to 31 is ideal. This combination matches international injection guidelines for subcutaneous therapies. Since the scale on a U-100 syringe shows 100 units (IU) per 1 ml, you can learn how to correctly convert the markings to your peptide dose in the FAQ on converting units to ml.

Here's what to look for when choosing your syringes:

• Volume (0.3 / 0.5 / 1.0 milliliters): For dose calculation, the syringe volume does not matter as long as U-100 is on the syringe: One unit always equals 0.01 milliliters. Smaller syringes are easier to read because the tick marks are farther apart, but they do not guarantee higher measurement accuracy. In a comparative study, finer markings improved neither accuracy nor repeatability. For peptide amounts below 0.5 milliliters, 0.3- or 0.5-milliliter models are more manageable. The injection calculator calculates the required units for you directly.
• Needle length: For injections into the subcutaneous fat tissue, 4-8 mm is safe according to the FIT/FITTER expert recommendation. An 8 mm needle covers almost all adults; longer needles (12.7 mm or 1/2 inch) carry the risk of accidentally hitting the muscle.
• Gauge (needle thickness): A higher gauge means a thinner needle. The standard for peptides is 29-31 G. While thin needles are less painful, thicker needles make it easier to draw up viscous solutions.
• Injection angle: With short needles (4-8 mm), you inject at a 90-degree angle without a skin fold. For needle lengths of 12.7 mm or more, the injection should be given into a lifted skin fold.
• Prefilled pen vs. insulin syringe: Approved GLP-1 medications like semaglutide (Ozempic, Wegovy) usually use prefilled pens. When reconstituting peptides from a vial, on the other hand, you use classic insulin syringes and suitable draw-up needles.

Use a new, sterile syringe for each vial. Reusing it dulls the needle tip, which can lead to pain and tissue irritation. The FAQ on injection sites and subcutaneous technique explains which body areas are suitable.

A peptide is an organic compound made of a short chain of amino acids, the building blocks of proteins. According to the US Food and Drug Administration (FDA), a peptide consists of chains of about 2 to 40 amino acids; longer compounds are classified as proteins.

In the human body, peptides often act as signaling molecules or peptide hormones. They control key processes such as metabolism, the feeling of fullness, inflammatory responses, and hormone release. Well-known examples include insulin for blood sugar regulation, GLP-1 (known through drugs like semaglutide in Ozempic), and the regenerative peptide BPC-157. Because of their small size, these compounds can precisely mimic the body's own signals.

For detailed information on individual substances, their scientific evidence, and safety notes, check out the Peptide Library.

Peptides are molecules made of amino acids. In water, they are chemically unstable: water speeds up breakdown processes like hydrolysis, aggregation, and oxidation. So a ready-to-use peptide solution can lose measurable purity after just a few days. A freeze-dried peptide powder, by contrast, stays stable for years when kept cool, dark, and dry. That is why manufacturers usually ship peptides as a powder.

Lyophilization, also called freeze-drying, is a way to preserve pharmaceuticals. The peptide solution is deep-frozen, and the water is removed in a vacuum by sublimation, meaning it goes straight from solid to gas. What is left is a stable, porous cake that you can later dissolve with sterile water. The international guideline ICH Q1A(R2) from the regulatory agencies FDA and EMA sets the standards for testing the stability and shelf life of such freeze-dried active substances.

Unopened, dry peptide vials do not need a continuous cold chain during shipping because they are in powder form. However, once you reconstitute the peptide with water, the chemical stability drops significantly. For how to store powder and dissolved active substances at the right temperature, see the guide to peptide storage and shelf life; answers to common questions are in the FAQ on storing lyophilisate powder.

Peptides generally cannot be taken orally or swallowed, because digestive enzymes in the gastrointestinal tract break down the molecules before they reach the bloodstream. The oral bioavailability - the proportion of the intact active substance that reaches the bloodstream - is practically zero percent for unprotected peptides.

The central exception among peptide drugs is oral semaglutide (brand name Rybelsus), a GLP-1 peptide combined with the excipient SNAC. This excipient briefly opens a pathway for the peptide to be absorbed through the stomach lining. According to the FDA label, the bioavailability after oral administration is still only about 0.4 to 1 percent, which pharmacokinetic analyses in PMC confirm. To achieve effective blood levels, the dose therefore has to be many times higher than the injection dose.

For all other peptides that come as a lyophilisate (freeze-dried powder) in a vial, swallowing or drinking them orally does not produce a measurable blood level, based on current knowledge. Stomach acid and enzymes break the peptide down completely into individual amino acids, so no peptide effect occurs. Why oral semaglutide works despite this and which mechanisms are used is explained on the semaglutide page in the peptide library.

The difference between peptides and proteins comes down to chain length: according to the US Food and Drug Administration (FDA), a chain of up to 40 amino acids is a peptide, while a chain of 41 or more is a protein. So peptides are the shorter molecules when you compare them directly to the larger proteins.

The two classes also differ in structure. Proteins usually fold into a complex three-dimensional shape with several subunits, which makes them more sensitive to heat, acid, and enzymes. Peptides stay shorter and often only form loose helices or hairpin shapes. That is why therapeutically used peptides are often modified, for example by attaching a fatty acid to make them last longer in the body. You can find a summary of what exactly makes a peptide in the FAQ "What exactly is a peptide?".

The 40-amino-acid limit is a regulatory decision by the FDA, not a fixed biological constant. Beyond this length, a drug in the US generally needs a biologics license (BLA) instead of a classic drug approval (NDA). Some in the scientific community discuss 50 amino acids as the threshold, but the FDA created legal clarity with the 40-amino-acid limit; the details are set out in the Federal Register and in 21 CFR § 600.3.